^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies
Published date:
12/21/2023
Excerpt:
Disease control rate (PR+SD) was 63%. Of the responders in PR, 3/4pts had documented PTEN mutations (3/5 pts enrolled with PTEN mutations had PR); 2/4 of pts in PR had co-mutations (pt with leiomyosarcoma had both PTEN and TSC; pt with breast cancer had both PTEN and STK11); 1/4 pts in PR had AKT and mTOR mutation....The safety profile of mTORC1/2 inhibitor sapanisertib in combination with metformin was generally tolerable, with anti-tumor activity observed in patients with advanced malignancies harboring PTEN/ AKT/mTOR pathway alterations.
Secondary therapy:
metformin
DOI:
10.1158/2767-9764.CRC-22-0260
